Use of ligand based models for protein domains to predict novel molecular targets and applications to triage affinity chromatography data

Journal of Proteome Research

Volumn 8, Issue 5, 2009, Pages 2575-2585

  Bender, Andreas ^a,b   Mikhailov, Dmitri ^a   Glick, Meir ^a   Scheiber, Josef ^a   Davies, John W ^a   Cleaver, Stephen ^c   Marshall, Stephen ^c   Tallarico, John A ^a   Harrington, Edmund ^a   Cornella Taracido, Ivan ^a   Jenkins, Jeremy L ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b LEIDEN UNIVERSITY   (Netherlands)

^c Novartis Institutes for Bio Medical Research Inc   (Netherlands)

Author keywords

Cheminformatics; Chemogenomics; Chemoproteomics; Extrapolation; Gefitinib; In silico; Iressa; Kinases; Protein domains; Pulldown; Resistance; Selectivity; Target prediction

Indexed keywords

DOPAMINE RECEPTOR; SEROTONIN RECEPTOR;

ARTICLE; CHEMICAL STRUCTURE; CHROMATOGRAPHY; COMPUTER MODEL; CONTROLLED STUDY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING; PROTEOMICS; STATISTICAL MODEL; VALIDATION PROCESS;

BINDING SITES; CHROMATOGRAPHY, AFFINITY; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEINS; PROTEOMICS; QUINAZOLINES; REPRODUCIBILITY OF RESULTS;

EID: 66749165862     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr900107z     Document Type: Article

References (48)

1. Simmons, D. L.; Botting, R. M.; Hla, T. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol. Rev . 2004, 56 , 387-437.
2. Fabian, M. A.; Biggs, W. H.; Treiber, D. K.; Atteridge, C. E. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol . 2005, 23 , 329-336.
3. Bantscheff, M.; Eberhard, D.; Abraham, Y.; Bastuck, S. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol . 2007, 25 , 1035-1044.
4. Hampton, T. "Promiscuous" anticancer drugs that hit multiple targets may thwart resistance. JAMA 2004, 292 , 419-422.
5. Bender, A.; Scheiber, J.; Glick, M.; Davies, J. W. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2007, 2 , 861-873.
6. Azzaoui, K.; Hamon, J.; Faller, B.; Whitebread, S. Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem 2007, 2 , 874-880.
7. Jenkins, J. L.; Bender, A.; Davies, J. W. In silico target fishing: Predicting biological targets from chemical structure. Drug Discovery Today: Technol . 2007, 3 , 413-421.
8. Chen, Y. Z.; Zhi, D. G. Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. Proteins 2001, 43 , 217-226.
9. Rockey, W. M.; Elcock, A. H. Rapid computational identification of the targets of protein kinase inhibitors. J. Med. Chem . 2005, 48 , 4138-4152.
10. Paul, N.; Kellenberger, E.; Bret, G.; Muller, P.; Rognan, D. Recovering the true targets of specific ligands by virtual screening of the Protein Data Bank. Proteins 2004, 54 , 671-680.
11. Warren, G. L.; Andrews, C. W.; Capelli, A.-M.; Clarke, B. A Critical Assessment of Docking Programs and Scoring Functions. J. Med. Chem . 2006, 49 , 5912-5931.
12. Cleves, A. E.; Jain, A. N. Robust ligand-based modeling of the biological targets of known drugs. J. Med. Chem . 2006, 49 , 2921-2938.
13. Nidhi; Glick, M.; Davies, J. W.; Jenkins, J. L. Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J. Chem. Inf. Model . 2006, 46 , 1124-1133.
14. Faulon, J. L.; Misra, M.; Martin, S.; Sale, K.; Sapra, R. Genome scale enzyme-metabolite and drug-target interaction predictions using the signature molecular descriptor. Bioinformatics 2008, 24 , 225-233.
15. Glen, R. C.; Bender, A.; Arnby, C. H.; Carlsson, L. Circular fingerprints: Flexible molecular descriptors with applications from physical chemistry to ADME. IDrugs 2006, 9 , 199-204.
16. Faulon, J. L.; Visco, D. P., Jr.; Pophale, R. S. The signature molecular descriptor. 1. Using extended valence sequences in QSAR and QSPR studies. J. Chem. Inf. Comput. Sci . 2003, 43 , 707-720.
17. Crisman, T. J.; Parker, C. N.; Jenkins, J. L.; Scheiber, J. Understanding false positives in reporter gene assays: in silico chemogenomics approaches to prioritize cell-based HTS data. J. Chem Inf. Model . 2007, 47 , 1319-1327.
18. Nettles, J. H.; Jenkins, J. L.; Bender, A.; Deng, Z. Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. J. Med. Chem . 2006, 49 , 6802-6810.
19. Bender, A.; Young, D. W.; Jenkins, J. L.; Serrano, M. Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. Comb. Chem. High Throughput Screening 2007, 10 , 719-731.
20. Strombergsson, H.; Kryshtafovych, A.; Prusis, P.; Fidelis, K. Generalized modeling of enzyme-ligand interactions using proteoch- emometrics and local protein substructures. Proteins 2006, 65 , 568-579.
21. Strombergsson, H.; Prusis, P.; Midelfart, H.; Lapinsh, M. Rough set-based proteochemometrics modeling of G-protein-coupled receptor-ligand interactions. Proteins 2006, 63 , 24-34.
22. Snyder, K. A.; Feldman, H. J.; Dumontier, M.; Salama, J. J.; Hogue, C. W. V. Domain-based small molecule binding site annotation. BMC Bioinf . 2006, 7 , 152.
23. WOrld of Molecular BioAcTivity (WOMBAT), available from Sunset Molecular Discovery LLC, http://www.sunsetmolecular.com/.
24. Apweiler, R.; Attwood, T. K.; Bairoch, A.; Bateman, A. The InterPro database, an integrated documentation resource for protein families, domains and functional sites. Nucleic Acids Res . 2001, 29 , 37-40.
25. Mulder, N. J.; Apweiler, R.; Attwood, T. K.; Bairoch, A. InterPro, progress and status in 2005. Nucleic Acids Res . 2005, 33 , D201- 205.
26. Mulder, N. J.; Apweiler, R.; Attwood, T. K.; Bairoch, A. New developments in the InterPro database. Nucleic Acids Res . 2007, 35 , D224-228.
27. Mano, N.; Sato, K.; Goto, J. Specific affinity extraction method for small molecule-binding proteins. Anal. Chem . 2006, 78 , 4668-4675.
28. Szardenings, K.; Li, B.; Ma, L.; Wu, M. Fishing for targets: novel approaches using small molecule baits. Drug Discovery Today: Technol . 2004, 1 , 9-15.
29. Brown, D.; Superti-Furga, G. Rediscovering the sweet spot in drug discovery. Drug Discovery Today 2003, 8 , 1067-1077.
30. Oda, Y.; Owa, T.; Sato, T.; Boucher, B. Quantitative chemical proteomics for identifying candidate drug targets. Anal. Chem . 2003, 75 , 2159-2165.
31. Kuster, B.; Schirle, M.; Mallick, P.; Aebersold, R. Scoring proteomes with proteotypic peptide probes. Nat. Rev. Mol. Cell Biol . 2005, 6 , 577-583.
32. Knockaert, M.; Gray, N.; Damiens, E.; Chang, Y. T. Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Chem. Biol . 2000, 7 , 411-422.
33. Katayama, H.; Oda, Y. Chemical proteomics for drug discovery based on compound-immobilized affinity chromatography. J. Chro- matogr., B 2007, 855 , 21-27.
34. Shiyama, T.; Furuya, M.; Yamazaki, A.; Terada, T.; Tanaka, A. Design and synthesis of novel hydrophilic spacers for the reduction of nonspecific binding proteins on affinity resins. Bioorg. Med. Chem . 2004, 12 , 2831-2841.
35. Gilmore, J. M.; Auberry, D. L.; Sharp, J. L.; White, A. M. A Bayesian estimator of protein-protein association probabilities. Bioinfor- matics 2008, 24 , 1554-1555.
36. PipelinePilot 5.1, available from Scitegic. http://www.scitegic.com/.
37. SRS (Sequence Retrieval System), http://srs6.ebi.ac.uk.
38. Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate-a practical and powerful approach to multiple testing. J. R. Stat. Soc., Ser. B 1995, 57 , 289-300.
39. Macchiarulo, A.; Nobeli, I.; Thornton, J. M. Ligand selectivity and competition between enzymes in silico. Nat. Biotechnol . 2004, 22 , 1039-1045.
40. Arkin, M. R.; Wells, J. A. Small-molecule inhibitors of protein- protein interactions: progressing towards the dream. Nat. Rev. Drug Discovery 2004, 3 , 301-317.
41. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science 2002, 298 , 1912-1934.
42. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol . 2008, 26 , 127-132.
43. McDonald, P. H.; Cote, N. L.; Lin, F. T.; Premont, R. T. Identification of NSF as a beta-arrestin1-binding protein. Implications for beta2-adrenergic receptor regulation. J. Biol. Chem . 1999, 274 , 10677-10680.
44. Buchanan, F. G.; DuBois, R. N. Emerging roles of beta-arrestins. Cell Cycle 2006, 5 , 2060-2063.
45. Sun, Y.; Cheng, Z.; Ma, L.; Pei, G. Beta-arrestin2 is criticallyinvolved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J. Biol. Chem . 2002, 277 , 49212-49219.
46. Buchanan, F. G.; Gorden, D. L.; Matta, P.; Shi, Q. Role of betaarrestin 1 in the metastatic progression of colorectal cancer. Proc. Natl. Acad. Sci. U.S.A . 2006, 103 , 1492-1497.
47. Elkind, N. B.; Szentpetery, Z.; Apati, A.; Ozvegy-Laczka, C. Multi- drug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res . 2005, 65 , 1770-1777.
48. Li, J.; Cusatis, G.; Brahmer, J.; Sparreboom, A. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol. Ther . 2007, 6 , 432-438.